SCHEMBL1967413

SCHEMBL1967413

CCCCN(C(=O)c1c(Cl)cccc1Cl)c1nnc(-c2cc(C)c(OC)c(C)c2)s1

nearest known ligand 0.57

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
HPGD P15428 1/20 0.57
UBE2N P61088 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HSD17B10 Q99714 1/20 0.57
S1PR1 P21453 19/20 0.55
S1PR3 Q99500 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968240 0.90 S1PR1 (0.67) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1964962 0.85 S1PR1 (0.64) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1966161 0.85 S1PR1 (0.68) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1967851 0.84 S1PR1 (0.77) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1966944 0.83 S1PR1 (0.60) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1966747 0.83 S1PR1 (0.69) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1971713 0.83 S1PR1 (0.71) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1966359 0.83 KDM4E (0.55) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1968031 0.82 S1PR1 (0.61) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1969999 0.82 HSD17B10 (0.56) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110200557-A1 NEW 2-AMIDOTHIADIAZOLE DERIVATIVES ALMIRALL, S.A. (ES) 2011-08-18 US claimed
EP-2177521-A1 New 2-Amidothiadiazole Derivatives Almirall, S.A. (ES) 2010-04-21 EP claimed
US-20110200557-A1 NEW 2-AMIDOTHIADIAZOLE DERIVATIVES ALMIRALL, S.A. (ES) 2011-08-18 US disclosed
US-20110200557-A1 NEW 2-AMIDOTHIADIAZOLE DERIVATIVES ALMIRALL, S.A. (ES) 2011-08-18 US disclosed
US-20110200557-A1 NEW 2-AMIDOTHIADIAZOLE DERIVATIVES ALMIRALL, S.A. (ES) 2011-08-18 US disclosed
EP-2334670-A1 NEW 2-AMIDOTHIADIAZOLE DERIVATIVES Almirall S.A. (ES) 2011-06-22 EP disclosed
WO-2010043377-A1 NEW 2-AMIDOTHIADIAZOLE DERIVATIVES ALMIRALL, S.A. (ES) 2010-04-22 WO disclosed
WO-2010043377-A1 NEW 2-AMIDOTHIADIAZOLE DERIVATIVES ALMIRALL, S.A. (ES) 2010-04-22 WO disclosed
EP-2177521-A1 New 2-Amidothiadiazole Derivatives Almirall, S.A. (ES) 2010-04-21 EP disclosed
EP-2177521-A1 New 2-Amidothiadiazole Derivatives Almirall, S.A. (ES) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110200557-A1 NEW 2-AMIDOTHIADIAZOLE DERIVATIVES S1PR2, S1PR3, S1PR1 KDM4E 4607/4885ALDH1A1 1610/4885HPGD 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.